 Mary Bessesen
Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcal Infections | 8 | 2024 | 390 | 2.460 |
Why?
| | Respiratory Protective Devices | 6 | 2021 | 15 | 2.260 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 7 | 2024 | 249 | 2.250 |
Why?
| | Nasal Cavity | 5 | 2024 | 62 | 1.940 |
Why?
| | Carrier State | 5 | 2024 | 79 | 1.930 |
Why?
| | Intraabdominal Infections | 8 | 2024 | 12 | 1.730 |
Why?
| | Bacteremia | 6 | 2020 | 221 | 1.390 |
Why?
| | Nose | 3 | 2024 | 68 | 1.360 |
Why?
| | Infection Control | 8 | 2023 | 172 | 1.340 |
Why?
| | Cross Infection | 7 | 2023 | 262 | 1.290 |
Why?
| | Health Personnel | 10 | 2021 | 748 | 1.230 |
Why?
| | Respiratory Tract Infections | 5 | 2021 | 398 | 1.010 |
Why?
| | Equipment Reuse | 2 | 2015 | 18 | 0.910 |
Why?
| | Disinfection | 2 | 2015 | 129 | 0.810 |
Why?
| | Masks | 4 | 2021 | 70 | 0.790 |
Why?
| | Diabetic Foot | 2 | 2020 | 26 | 0.760 |
Why?
| | Microbiota | 2 | 2024 | 781 | 0.750 |
Why?
| | Rifampin | 2 | 2020 | 82 | 0.750 |
Why?
| | Osteomyelitis | 2 | 2020 | 143 | 0.660 |
Why?
| | Antimicrobial Stewardship | 1 | 2023 | 130 | 0.660 |
Why?
| | Veterans | 3 | 2020 | 1603 | 0.580 |
Why?
| | Staphylococcus aureus | 3 | 2018 | 460 | 0.540 |
Why?
| | Influenza, Human | 5 | 2022 | 617 | 0.520 |
Why?
| | Sepsis | 1 | 2023 | 641 | 0.500 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2018 | 246 | 0.440 |
Why?
| | Evolution, Molecular | 1 | 2018 | 515 | 0.410 |
Why?
| | HIV Infections | 4 | 2018 | 3154 | 0.410 |
Why?
| | Anti-HIV Agents | 2 | 2018 | 888 | 0.400 |
Why?
| | Anti-Bacterial Agents | 7 | 2024 | 1915 | 0.400 |
Why?
| | Medication Adherence | 1 | 2018 | 539 | 0.400 |
Why?
| | Pregnancy Complications, Infectious | 7 | 2024 | 428 | 0.390 |
Why?
| | Genomics | 1 | 2018 | 836 | 0.370 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 1999 | 130 | 0.360 |
Why?
| | Polymers | 1 | 2015 | 499 | 0.340 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2012 | 278 | 0.330 |
Why?
| | Humans | 50 | 2024 | 144957 | 0.320 |
Why?
| | Occupational Exposure | 2 | 2019 | 354 | 0.320 |
Why?
| | Osteoporosis | 1 | 2012 | 236 | 0.310 |
Why?
| | Catheters, Indwelling | 1 | 2010 | 96 | 0.300 |
Why?
| | Delivery of Health Care | 6 | 2022 | 947 | 0.300 |
Why?
| | Catheter-Related Infections | 1 | 2010 | 94 | 0.290 |
Why?
| | Catheterization, Central Venous | 1 | 2010 | 123 | 0.280 |
Why?
| | Escherichia coli Infections | 2 | 2013 | 129 | 0.270 |
Why?
| | Influenza Vaccines | 2 | 2022 | 529 | 0.250 |
Why?
| | Adult | 20 | 2024 | 40506 | 0.240 |
Why?
| | Female | 24 | 2024 | 78376 | 0.230 |
Why?
| | Elastomers | 2 | 2015 | 31 | 0.220 |
Why?
| | Diagnostic Imaging | 5 | 2024 | 339 | 0.220 |
Why?
| | Diverticulitis | 1 | 2024 | 8 | 0.220 |
Why?
| | Abdominal Abscess | 1 | 2024 | 25 | 0.210 |
Why?
| | Cholangitis | 1 | 2024 | 23 | 0.210 |
Why?
| | Blood Culture | 1 | 2024 | 25 | 0.210 |
Why?
| | Cholecystitis, Acute | 1 | 2024 | 24 | 0.210 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1999 | 235 | 0.210 |
Why?
| | Mycobacterium avium | 1 | 2004 | 21 | 0.210 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2004 | 19 | 0.210 |
Why?
| | Male | 21 | 2024 | 72406 | 0.200 |
Why?
| | Molecular Typing | 1 | 2013 | 21 | 0.200 |
Why?
| | Mycobacterium avium-intracellulare Infection | 2 | 2004 | 63 | 0.200 |
Why?
| | Polymerase Chain Reaction | 3 | 2015 | 1054 | 0.200 |
Why?
| | Peritonitis | 1 | 2004 | 84 | 0.190 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2013 | 81 | 0.190 |
Why?
| | Middle Aged | 13 | 2020 | 35928 | 0.190 |
Why?
| | Risk Factors | 6 | 2021 | 10792 | 0.190 |
Why?
| | Appendicitis | 1 | 2024 | 148 | 0.190 |
Why?
| | Clostridium Infections | 1 | 2023 | 74 | 0.180 |
Why?
| | Coronavirus OC43, Human | 1 | 2021 | 7 | 0.180 |
Why?
| | Pregnancy | 8 | 2024 | 7191 | 0.170 |
Why?
| | Orthomyxoviridae Infections | 1 | 2022 | 72 | 0.170 |
Why?
| | Feasibility Studies | 2 | 2015 | 1095 | 0.160 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2022 | 157 | 0.160 |
Why?
| | Aged | 6 | 2020 | 25947 | 0.160 |
Why?
| | Escherichia coli | 2 | 2013 | 855 | 0.160 |
Why?
| | Cohort Studies | 4 | 2020 | 5965 | 0.160 |
Why?
| | United States | 10 | 2024 | 15988 | 0.150 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2019 | 20 | 0.150 |
Why?
| | Placebos | 1 | 2020 | 193 | 0.150 |
Why?
| | Attitude | 1 | 2021 | 261 | 0.150 |
Why?
| | Hepatitis B, Chronic | 1 | 1999 | 22 | 0.150 |
Why?
| | Lamivudine | 1 | 1999 | 65 | 0.150 |
Why?
| | Foot | 1 | 2020 | 100 | 0.140 |
Why?
| | Viruses | 1 | 2021 | 165 | 0.140 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 129 | 0.140 |
Why?
| | Financing, Government | 1 | 1999 | 53 | 0.140 |
Why?
| | Risk Assessment | 4 | 2024 | 3676 | 0.140 |
Why?
| | Secondary Prevention | 1 | 2020 | 255 | 0.140 |
Why?
| | Mandatory Programs | 1 | 2018 | 16 | 0.140 |
Why?
| | Retrospective Studies | 7 | 2020 | 17101 | 0.140 |
Why?
| | Aged, 80 and over | 3 | 2020 | 8279 | 0.140 |
Why?
| | Outpatients | 1 | 2021 | 443 | 0.130 |
Why?
| | Sterilization | 1 | 2017 | 24 | 0.130 |
Why?
| | Hospitalization | 3 | 2018 | 2434 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 966 | 0.130 |
Why?
| | Vaccination Coverage | 1 | 2018 | 103 | 0.130 |
Why?
| | Herpes Zoster Vaccine | 1 | 2018 | 154 | 0.120 |
Why?
| | Antibiosis | 1 | 2015 | 10 | 0.120 |
Why?
| | Streptococcus mitis | 1 | 2015 | 10 | 0.120 |
Why?
| | Lactobacillus | 1 | 2015 | 28 | 0.120 |
Why?
| | Treatment Outcome | 5 | 2020 | 11695 | 0.110 |
Why?
| | Catalase | 1 | 2015 | 130 | 0.110 |
Why?
| | Pyrimethamine | 1 | 1995 | 3 | 0.110 |
Why?
| | Sulfadoxine | 1 | 1995 | 4 | 0.110 |
Why?
| | Vaccination | 3 | 2021 | 1423 | 0.110 |
Why?
| | Nasal Mucosa | 1 | 2016 | 112 | 0.110 |
Why?
| | Disease Transmission, Infectious | 1 | 2015 | 69 | 0.110 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 189 | 0.110 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1995 | 34 | 0.110 |
Why?
| | Double-Blind Method | 1 | 2020 | 2029 | 0.110 |
Why?
| | Equipment Contamination | 1 | 2015 | 71 | 0.110 |
Why?
| | Reference Standards | 1 | 2015 | 178 | 0.110 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 824 | 0.110 |
Why?
| | Herpes Zoster | 1 | 2018 | 315 | 0.110 |
Why?
| | Efficiency, Organizational | 2 | 2018 | 140 | 0.110 |
Why?
| | Occupational Diseases | 1 | 2016 | 165 | 0.100 |
Why?
| | Child | 9 | 2024 | 22657 | 0.100 |
Why?
| | Hospitals, Veterans | 1 | 2015 | 259 | 0.100 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 636 | 0.100 |
Why?
| | Medical Errors | 1 | 2015 | 118 | 0.100 |
Why?
| | Virus Diseases | 1 | 2016 | 216 | 0.100 |
Why?
| | Task Performance and Analysis | 1 | 2015 | 198 | 0.100 |
Why?
| | Mycobacterium Infections | 1 | 1993 | 61 | 0.100 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 559 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5417 | 0.100 |
Why?
| | HIV-1 | 1 | 1999 | 896 | 0.090 |
Why?
| | Prospective Studies | 3 | 2020 | 7997 | 0.090 |
Why?
| | Bone Density Conservation Agents | 1 | 2012 | 81 | 0.090 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1325 | 0.090 |
Why?
| | Osteoporotic Fractures | 1 | 2012 | 61 | 0.090 |
Why?
| | Biomarkers | 1 | 2023 | 4275 | 0.090 |
Why?
| | Prevalence | 2 | 2013 | 2836 | 0.090 |
Why?
| | Acute Disease | 2 | 2024 | 1031 | 0.090 |
Why?
| | Intensive Care Units | 2 | 2015 | 916 | 0.090 |
Why?
| | Incidence | 2 | 2019 | 2883 | 0.080 |
Why?
| | Ergonomics | 1 | 2010 | 29 | 0.080 |
Why?
| | United States Department of Veterans Affairs | 1 | 2015 | 768 | 0.080 |
Why?
| | Longitudinal Studies | 2 | 2015 | 2947 | 0.080 |
Why?
| | Listeria monocytogenes | 1 | 1990 | 116 | 0.070 |
Why?
| | Metagenome | 1 | 2010 | 149 | 0.070 |
Why?
| | Colorado | 2 | 2018 | 4564 | 0.070 |
Why?
| | Molecular Epidemiology | 2 | 2013 | 73 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2004 | 1048 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2925 | 0.060 |
Why?
| | Cytosine | 1 | 2005 | 51 | 0.060 |
Why?
| | Organophosphonates | 1 | 2005 | 97 | 0.050 |
Why?
| | Herpes Simplex | 1 | 2005 | 98 | 0.050 |
Why?
| | Immunocompetence | 1 | 2004 | 47 | 0.050 |
Why?
| | Fluoroquinolones | 1 | 2013 | 45 | 0.050 |
Why?
| | beta-Lactams | 1 | 2013 | 32 | 0.050 |
Why?
| | Adolescent | 3 | 2020 | 22453 | 0.050 |
Why?
| | Ambulatory Care | 2 | 2019 | 603 | 0.050 |
Why?
| | Young Adult | 1 | 2020 | 14126 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 423 | 0.050 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2022 | 38 | 0.050 |
Why?
| | Virulence Factors | 1 | 2013 | 174 | 0.040 |
Why?
| | Inpatients | 2 | 2020 | 546 | 0.040 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2022 | 50 | 0.040 |
Why?
| | Escherichia coli Proteins | 1 | 2013 | 206 | 0.040 |
Why?
| | Nurses | 1 | 2023 | 178 | 0.040 |
Why?
| | Hepatitis B e Antigens | 1 | 1999 | 3 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2005 | 768 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2023 | 901 | 0.040 |
Why?
| | Program Evaluation | 2 | 2015 | 949 | 0.040 |
Why?
| | Drug Resistance | 1 | 1999 | 153 | 0.040 |
Why?
| | Genotype | 1 | 2013 | 1835 | 0.030 |
Why?
| | Treatment Failure | 1 | 1999 | 365 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2022 | 672 | 0.030 |
Why?
| | Absenteeism | 1 | 2018 | 53 | 0.030 |
Why?
| | Surgical Instruments | 1 | 2017 | 51 | 0.030 |
Why?
| | Hospital Costs | 1 | 2017 | 124 | 0.030 |
Why?
| | Immunization Programs | 1 | 2018 | 194 | 0.030 |
Why?
| | Hand Hygiene | 1 | 2015 | 9 | 0.030 |
Why?
| | Recurrence | 1 | 1999 | 1135 | 0.030 |
Why?
| | Operating Rooms | 1 | 2017 | 146 | 0.030 |
Why?
| | Pentamidine | 1 | 1995 | 3 | 0.030 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 38 | 0.030 |
Why?
| | Personal Protective Equipment | 1 | 2015 | 57 | 0.030 |
Why?
| | Seasons | 1 | 2018 | 556 | 0.030 |
Why?
| | Zidovudine | 1 | 1995 | 77 | 0.030 |
Why?
| | Health Policy | 1 | 2018 | 401 | 0.030 |
Why?
| | Workplace | 1 | 2016 | 274 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 1995 | 575 | 0.020 |
Why?
| | Occupational Health | 1 | 2015 | 209 | 0.020 |
Why?
| | Global Health | 1 | 2015 | 401 | 0.020 |
Why?
| | Digestive System | 1 | 1991 | 28 | 0.020 |
Why?
| | Listeria | 1 | 1990 | 5 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2015 | 590 | 0.020 |
Why?
| | Patients' Rooms | 1 | 2010 | 13 | 0.020 |
Why?
| | Facility Design and Construction | 1 | 2010 | 12 | 0.020 |
Why?
| | Manikins | 1 | 2010 | 35 | 0.020 |
Why?
| | Time and Motion Studies | 1 | 2010 | 28 | 0.020 |
Why?
| | Diarrhea | 1 | 1991 | 192 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1990 | 166 | 0.020 |
Why?
| | Hand Disinfection | 1 | 2010 | 26 | 0.020 |
Why?
| | Bacterial Typing Techniques | 1 | 2010 | 44 | 0.020 |
Why?
| | Colony Count, Microbial | 1 | 2010 | 122 | 0.020 |
Why?
| | DNA, Ribosomal | 1 | 2010 | 94 | 0.020 |
Why?
| | Quality Control | 1 | 2010 | 163 | 0.020 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 1995 | 366 | 0.020 |
Why?
| | Health | 1 | 2010 | 81 | 0.020 |
Why?
| | Staphylococcus epidermidis | 1 | 2010 | 79 | 0.020 |
Why?
| | Feedback | 1 | 2010 | 181 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2018 | 1099 | 0.020 |
Why?
| | Problem Solving | 1 | 2010 | 156 | 0.020 |
Why?
| | Checklist | 1 | 2010 | 108 | 0.020 |
Why?
| | Species Specificity | 1 | 1990 | 574 | 0.020 |
Why?
| | Time Factors | 2 | 2010 | 7183 | 0.020 |
Why?
| | Equipment Design | 1 | 2010 | 530 | 0.020 |
Why?
| | Workload | 1 | 2010 | 170 | 0.020 |
Why?
| | Cues | 1 | 2010 | 326 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 342 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 378 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2009 | 174 | 0.020 |
Why?
| | Attention | 1 | 2010 | 458 | 0.020 |
Why?
| | Biodiversity | 1 | 2010 | 426 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2931 | 0.010 |
Why?
| | Motivation | 1 | 2010 | 610 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1990 | 1990 | 0.010 |
Why?
| | Simplexvirus | 1 | 2005 | 82 | 0.010 |
Why?
| | Drug Resistance, Viral | 1 | 2005 | 123 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 294 | 0.010 |
Why?
| | Bacteria | 1 | 1990 | 889 | 0.010 |
Why?
| | Life Tables | 1 | 1995 | 21 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1995 | 277 | 0.010 |
Why?
| | Mycobacterium avium Complex | 1 | 1995 | 88 | 0.010 |
Why?
| | Australia | 1 | 1995 | 286 | 0.010 |
Why?
| | North America | 1 | 1995 | 310 | 0.010 |
Why?
| | Europe | 1 | 1995 | 412 | 0.010 |
Why?
| | Survival Rate | 1 | 1995 | 2092 | 0.000 |
Why?
| | Case-Control Studies | 1 | 1995 | 3608 | 0.000 |
Why?
|
|
Bessesen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|